A Phase 2 interventional study of ISIS 678354 and Placebo in Hypertriglyceridemia and Cardiovascular Diseases, sponsored by Akcea Therapeutics. Completed at 31 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-11.
Sponsored by Akcea Therapeutics (part of Ionis Pharmaceuticals, Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..
Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 2, and was the 6th registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2018.
This study's enrollment of 114 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 114 across the 12 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Akcea Therapeutics, one of the names counted as Ionis Pharmaceuticals, Inc.. Under that name alone:
Akcea Therapeutics is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
2 of the studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT07604974Ionis Pharmaceuticals, Inc.A Study to Assess the Safety, Tolerability and Efficacy of ION775 | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants with hypertriglyceridemia and established CVD or at a high risk for CVD.
Key Inclusion Criteria:
Key Exclusion Criteria:
Type 2 diabetes mellitus with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in each cohort (A, B, C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
Drug: Placebo
Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
Drug: ISIS 678354
Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
Drug: ISIS 678354
Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
Drug: ISIS 678354
Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
Drug: ISIS 678354
ISIS 678354 solution for SC injection.
Also known as: AKCEA-APOCIII-LRx, IONIS-APOCIII-LRx
Sterile Normal Saline (0.9% NaCl).
Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point
An analysis of covariance (ANCOVA) model was performed on the log ratio of TG value at the Primary Analysis Time Point to TG value at Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: (ratio of TG value at the Primary Analysis Time Point to TG value at Baseline - 1) × 100.
Time frame: Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. A TEAE was defined as any AE starting on or after the first dose of the study drug.
Time frame: Up to the 13-week post-treatment follow-up period (Up to approximately 15 months)
Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point
An ANCOVA model was performed on the log ratio of Primary Analysis Time Point value to Baseline value for ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I. The estimate of the log ratio was converted back to the original scale and percent change for each lipid parameter was calculated using formula: (ratio of Primary Analysis Time Point value to Baseline value - 1) × 100.
Time frame: Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D)
Percentage of Participants Who Achieved Fasting Triglycerides (TG) <= 150 mg/dL (<= 1.7 Millimoles Per Liter [mmol/L])
The percentage of participants who achieved \<= 150 mg/dL or \<= 1.7 mmol/L of fasting TG levels at the primary analysis time point were compared between each ISIS 678354 treatment group and pooled placebo group using a logistic regression model with log-transformed baseline TG value as a covariate.
Time frame: Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D)
Percentage of Participants Who Achieved Fasting Triglycerides (TG) <= 100 mg/dL (<= 1.13 mmol/L)
The percentage of participants who achieved \<= 100 mg/dL or \<= 1.13 mmol/L of fasting TG levels at the primary analysis time point were compared between each ISIS 678354 treatment group and pooled placebo group using a logistic regression model with log-transformed baseline TG value as a covariate.
Time frame: Baseline and Month 6 (Week 25 for Cohorts A and B and Week 27 for Cohorts C and D)
Maximum Plasma Concentration (Cmax) of ISIS 678354
Time frame: Predose, 1, 2, 4, 8, 24 hours post the first dose (Day 1), Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D)
Time to Reach Maximum Plasma Concentration (Tmax) of ISIS 678354
Time frame: Predose, 1, 2, 4, 8, 24 hours post the first dose (Day 1), Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D)
Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours (AUC0-24) of ISIS 678354
Time frame: Predose, 1, 2, 4, 8, 24 hours post the first dose (Day 1), Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D)
Participants with a clinical diagnosis of hypertriglyceridemia and established cardiovascular disease (CVD) or at high risk for CVD were enrolled in 32 study sites in United States and Canada between 30 January 2018 to 25 February 2020.
| Milestone | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| Started | 24 | 22 | 23 | 23 | 22 |
| Completed | 22 | 19 | 20 | 19 | 22 |
| Not completed | 2 | 3 | 3 | 4 | 0 |
| Withdrew: Voluntary withdrawal | 2 | 3 | 2 | 3 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
An analysis of covariance (ANCOVA) model was performed on the log ratio of TG value at the Primary Analysis Time Point to TG value at Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: (ratio of TG value at the Primary Analysis Time Point to TG value at Baseline - 1) × 100.
| percent change | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point | 6 (-9 to 23) | -23 (-34 to -10) | -56 (-62 to -49) | -60 (-66 to -54) | -60 (-65 to -53) |
An adverse event (AE) was defined as any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. A TEAE was defined as any AE starting on or after the first dose of the study drug.
| Participants | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 20 | 17 | 20 | 22 | 21 |
An ANCOVA model was performed on the log ratio of Primary Analysis Time Point value to Baseline value for ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I. The estimate of the log ratio was converted back to the original scale and percent change for each lipid parameter was calculated using formula: (ratio of Primary Analysis Time Point value to Baseline value - 1) × 100.
| percent change | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| Apo-C III | 2 (-16 to 23) | -29 (-42 to -13) | -68 (-74 to -61) | -73 (-78 to -67) | -74 (-78 to -69) |
| TC | 1 (-6 to 7) | -2 (-8 to 5) | -12 (-17 to -5) | -3 (-9 to 4) | -8 (-13 to -2) |
| LDL-C | -2 (-13 to 11) | 5 (-7 to 19) | 2 (-10 to 15) | 27 (13 to 44) | 10 (-2 to 23) |
| HDL-C | -1 (-8 to 6) | 11 (3 to 19) | 33 (24 to 43) | 40 (30 to 51) | 29 (20 to 39) |
| Non-HDL-C | 1 (-8 to 10) | -6 (-15 to 3) | -24 (-31 to -17) | -15 (-23 to -7) | -19 (-26 to -12) |
| VLDL-C | -2 (-13 to 11) | -22 (-32 to -12) | -54 (-59 to -48) | -59 (-63 to -53) | -60 (-65 to -55) |
| ApoB | -2 (-8 to 5) | 0 (-7 to 8) | -17 (-23 to -12) | -7 (-13 to 0) | -12 (-18 to -6) |
| ApoA-1 | 0 (-4 to 4) | 5 (1 to 10) | 14 (9 to 19) | 18 (13 to 23) | 14 (9 to 18) |
The percentage of participants who achieved \<= 150 mg/dL or \<= 1.7 mmol/L of fasting TG levels at the primary analysis time point were compared between each ISIS 678354 treatment group and pooled placebo group using a logistic regression model with log-transformed baseline TG value as a covariate.
| percentage of participants | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Fasting Triglycerides (TG) <= 150 mg/dL (<= 1.7 Millimoles Per Liter [mmol/L]) | 4.2 | 13.6 | 65.2 | 73.9 | 90.9 |
The percentage of participants who achieved \<= 100 mg/dL or \<= 1.13 mmol/L of fasting TG levels at the primary analysis time point were compared between each ISIS 678354 treatment group and pooled placebo group using a logistic regression model with log-transformed baseline TG value as a covariate.
| percentage of participants | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Fasting Triglycerides (TG) <= 100 mg/dL (<= 1.13 mmol/L) | 0 | 0 | 30.4 | 26.1 | 45.5 |
| nanograms per milliliter (ng/mL) | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|
| Day 1 | 53.7 ± 181.2 | 45.9 ± 36.2 | 35.8 ± 71.1 | 48.8 ± 333.3 |
| Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D) | 41.0 ± 324.1 | 48.0 ± 29.9 | 45.1 ± 47.4 | 127 ± 29.9 |
| hours (h) | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|
| Day 1 | 1.08 (1.00 to 2.00) | 2.00 (1.98 to 4.00) | 3.03 (2.00 to 4.00) | 1.50 (1.05 to 1.95) |
| Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D) | 2.00 (0.917 to 8.00) | 2.08 (1.00 to 4.00) | 2.50 (1.00 to 4.00) | 4.04 (4.02 to 4.07) |
| nanograms*hours per milliliter (ng*h/mL) | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|
| Day 1 | 618 ± 115.6 | 499 ± 31.1 | 411 ± 59.0 | 563 ± 334.6 |
| Week 21 (for Cohorts A and B) and Week 25 (for Cohorts C and D) | 468 ± 258.4 | 499 ± 11.2 | 454 ± 26.3 | 1460 ± 13.6 |
Collected over Up to the 13-week post-treatment follow-up period (Up to approximately 15 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pooled Placebo | 0/24 (0%) | 2/24 (8.3%) | 16/24 (66.7%) |
| Cohort A: ISIS 678354: 10 mg Q4W | 0/22 (0%) | 3/22 (13.6%) | 15/22 (68.2%) |
| Cohort C: ISIS 678354: 15 mg Q2W | 1/23 (4.3%) | 4/23 (17.4%) | 19/23 (82.6%) |
| Cohort D: ISIS 678354: 10 mg QW | 0/23 (0%) | 1/23 (4.3%) | 20/23 (87%) |
| Cohort B: ISIS 678354: 50 mg Q4W | 0/22 (0%) | 3/22 (13.6%) | 22/22 (100%) |
| Event | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| Acute coronary syndromeCardiac disorders | 0/24 | 1/22 | 0/23 | 0/23 | 0/22 |
| Acute myocardial infarctionCardiac disorders | 0/24 | 0/22 | 0/23 | 0/23 | 1/22 |
| CardiomyopathyCardiac disorders | 0/24 | 0/22 | 0/23 | 0/23 | 1/22 |
| Supraventricular tachycardiaCardiac disorders | 0/24 | 0/22 | 0/23 | 0/23 | 1/22 |
| PneumoniaInfections and infestations | 0/24 | 1/22 | 0/23 | 0/23 | 1/22 |
| AstheniaGeneral disorders | 0/24 | 1/22 | 0/23 | 0/23 | 0/22 |
| Angina unstableCardiac disorders | 0/24 | 0/22 | 1/23 | 0/23 | 0/22 |
| Cardiac arrestCardiac disorders | 0/24 | 0/22 | 1/23 | 0/23 | 0/22 |
| InfluenzaInfections and infestations | 0/24 | 0/22 | 1/23 | 0/23 | 0/22 |
| CholelithiasisHepatobiliary disorders | 0/24 | 0/22 | 1/23 | 0/23 | 0/22 |
| Event | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/24 | 3/22 | 4/23 | 5/23 | 4/22 |
| Injection site erythemaGeneral disorders | 0/24 | 2/22 | 3/23 | 5/23 | 4/22 |
| Urinary tract infectionInfections and infestations | 1/24 | 2/22 | 2/23 | 1/23 | 4/22 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/24 | 1/22 | 0/23 | 2/23 | 4/22 |
| NauseaGastrointestinal disorders | 1/24 | 3/22 | 1/23 | 1/23 | 4/22 |
| Upper respiratory tract infectionInfections and infestations | 3/24 | 2/22 | 3/23 | 4/23 | 3/22 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/24 | 1/22 | 3/23 | 1/23 | 0/22 |
| SinusitisInfections and infestations | 1/24 | 0/22 | 2/23 | 0/23 | 3/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/24 | 3/22 | 3/23 | 3/23 | 2/22 |
| Back painMusculoskeletal and connective tissue disorders | 1/24 | 3/22 | 1/23 | 3/23 | 3/22 |
Full analysis set (FAS) included all participants who were randomized and received at least 1 dose of study drug (ISIS 678354 or placebo).
| Age, Continuous(years) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Mean | 64.6 ± 7.93 | 64.4 ± 9.13 | 68.9 ± 6.82 | 65.6 ± 8.48 | 62.9 ± 7.40 | 65.3 ± 8.10 |
| Sex: Female, Male(Participants) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 8 | 4 | 5 | 7 | 28 |
| Male | 20 | 14 | 19 | 18 | 15 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 2 | 1 | 0 | 7 |
| Not Hispanic or Latino | 23 | 19 | 21 | 22 | 22 | 107 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 0 | 2 | 4 |
| White | 22 | 20 | 23 | 23 | 18 | 106 |
| More than one race | 0 | 1 | 0 | 0 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Fasting Triglycerides (TG)(milligrams per deciliter (mg/dL)) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Mean | 293.8 ± 86.68 | 281.6 ± 73.43 | 284.8 ± 94.54 | 292.3 ± 89.29 | 268.4 ± 85.08 | 284.4 ± 85.16 |
| Apolipoprotein CIII (ApoC-III)(mg/dL) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Mean | 16.618 ± 4.4720 | 16.030 ± 4.1482 | 15.849 ± 4.2456 | 16.810 ± 4.2021 | 15.669 ± 3.2484 | 16.205 ± 4.0466 |
| Total Cholesterol (TC)(mg/dL) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Mean | 144.8 ± 26.00 | 149.2 ± 28.81 | 163.1 ± 35.09 | 160.0 ± 34.55 | 166.8 ± 35.30 | 156.7 ± 32.66 |
| LDL Cholesterol (LDL-C)(mg/dL) | Pooled Placebo | Cohort A: ISIS 678354: 10 mg Q4W | Cohort C: ISIS 678354: 15 mg Q2W | Cohort D: ISIS 678354: 10 mg QW | Cohort B: ISIS 678354: 50 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Mean | 55.9 ± 26.06 | 62.4 ± 22.57 | 73.1 ± 29.73 | 71.2 ± 30.24 | 74.8 ± 22.47 | 67.4 ± 27.02 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Nov 2019, 21 months.
Results were first posted in Jan 2023, 3 years 1 month after primary completion. A results delay was requested in Nov 2020.
Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 21 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olezarsen